@article {Timilsina2021.06.13.21258856, author = {Sanjay S. Timilsina and Nolan Durr and Mohamed Yafia and Hani Sallum and Pawan Jolly and Donald E. Ingber}, title = {Rapid antifouling nanocomposite coating enables highly sensitive multiplexed electrochemical detection of myocardial infarction and concussion markers}, elocation-id = {2021.06.13.21258856}, year = {2021}, doi = {10.1101/2021.06.13.21258856}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Here we describe an ultra-fast (\< 1 min) method for coating electrochemical (EC) sensors with an anti-fouling nanocomposite layer that can be stored at room temperature for months, which provides unprecedented sensitivity and selectivity for diagnostic applications. We leveraged this method to develop a multiplexed diagnostic platform for detection of biomarkers that could potentially be used to triage patients with myocardial infarction and traumatic brain injury using only 15 {\textmu}L of blood. Single-digit pg/mL sensitivity was obtained within minutes for all the biomarkers tested in unprocessed human plasma samples and whole blood, which is much faster and at least 50 times more sensitive than traditional ELISA methods, and the signal was stable enough to be measured after one week of storage. The multiplexed EC sensor platform was validated by analyzing 22 patient samples, which demonstrated excellent correlation with reported clinical values.Competing Interest StatementThis technology has been licensed to GBS Inc. for COVID-19 diagnostics. S.S.T., N.D., P.J. and D.E.I are listed as inventors on patents describing this technology. The remaining authors declare no competing interests.Funding StatementWe acknowledge research funding from the Wyss Institute for Biologically Inspired Engineering at Harvard University. M.Y. acknowledges Fonds de recherche du Quebec nature et technologie (FRQNT) postdoctoral fellowship $\#$260284.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were collected under the approval of the Institutional Review Board for Harvard Human Research Protection Program (IRB21-0024).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe main data supporting the results in this study are available within the paper and its Supplementary Information. All raw and processed data generated in this work, including the representative images provided in the manuscript, are available from the corresponding authors on reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/06/16/2021.06.13.21258856}, eprint = {https://www.medrxiv.org/content/early/2021/06/16/2021.06.13.21258856.full.pdf}, journal = {medRxiv} }